NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Ltd. Files Registration Statement for Proposed Follow-On Offering
NeuroDerm Ltd. today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering of its ordinary shares.
”> Read More
NeuroDerm Announces Start of a Pharmacokinetic, Head-To-Head Comparison Study of ND0612H and Duodopa
Study Will Determine Dosing and Bioavailability of the First, Subcutaneously Delivered Liquid Levodopa for the Treatment of Parkinson’s Disease vs. Intra-Duodenal Levodopa Gel Infusion Requiring Surgical Intervention. > Read More
NeuroDerm’s Latest Clinical Data Accepted as Late Breaking News to the International Parkinson and Movement Disorder Society’s 19th International Congress
NeuroDerm’s Latest Clinical Data Accepted as Late Breaking News to the International Parkinson and Movement Disorder Society’s 19th International Congress on June 14-18, 2015 in San Diego”> Read More